1.Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl 1): S12–S18.
2.Gerding DN, Muto CA, Owens RC. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008;46(suppl 1):S43–S49.
3.Kyne L, Hamel MB, Polavaram R, Kelly CRHealth care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346–353.
4.Kim KH, Fekety R, Batts DH, et al.Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981;143:42–50.
5.Huang SS, Datta R, Platt R. Risk of acquiring antibiotic-resistant bacteria from prior room occupants. Arch Intern Med 2006;166:1945–1951.
6.Chang VT, Nelson K. The role of physical proximity in nosocomial diarrhea. Clin Infect Dis 2000;31:717–722.
7.Dubberke ER, Reske KA, Olsen MA, et al.Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C. difficile-associated disease. Arch Intern Med 2007;167:1092–1097.
8. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2011. http://www.whocc.no/atcddd/. Accessed August 15, 2008.
9.Kazakova SV, Ware K, Baughman B, et al.A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006;166:2518–2524.
10.Muto CA, Pokrywka M, Shutt K, et al.A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273–280.
11.Loo VG, Poirier L, Miller MA, et al.A predominately clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.
12.Pepin J, Saheb N, Coulombe M, et al.Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–1260.
13.Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007;45:1543–1549.
14.Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008;46(suppl 1):S19–S31.
15.McCusker ME, Harris AD, Perencevich E, Roghmann M. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9:730–733.
16.Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;17(1):33–38.
17.Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhea. J Hosp Infect 2003;54:243–245.
18.Bliss DZ, Johnson S, Savik K, Clabots CR, Willard K, Gerding DN. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998;129:1012–1019.
19.American Institute of Architects. Guidelines for Design and Construction of Hospital and Healthcare Facilities. Washington, DC: American Institute of Architects Press, 2006.
20.Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007;44:664–670.
21.Boyce JM, Havill NL, Otter JA, et al.Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting. Infect Control Hosp Epidemiol 2008;29:723–729.